HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove,Superior at International Conference ( he spread of influenza viruses among hu...)

HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove,Superior at International Conference

he spread of influenza viruses among humans, including potentially the high pathogenicity H5N1 virus.

For additional information, please visit www.hepalife.com.

To receive future press releases via email, please visit: http://www.hepalife.com/alerts.php

To view the full HTML text of this release, please visit: http://www.hepalife.com/20070625-1.html.php

Legal Notice Regarding Forward-Looking Statements

No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although the Company believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, technological obsolescence of the Company's products, technical problems with the Company's research and products, price increases for supplies an
'"/>

Page: 1 2 3 4 5 6
Related medicine technology :

1. HepaLife Announces Scientific Presentation of PBS-1 Cell Line at International Influenza Meeting
2. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
3. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
4. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
5. In Vitro and In Vivo Data Show Alfacells Onocanse is Active Against Naive and Chemoresistant Neuroblastoma Cells
6. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
7. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
8. Pluristems PLX Cells Demonstrate Potential to Treat Parkinsons Disease
9. Refrigerated Stem Cells Survive 12 Times Longer with ProtoKinetixs AAGP
10. Stanford Researchers Track Human Stem Cells Transplanted Into Rat Brain
11. ProtoKinetixs AAGP Dramatically Increases Recovery Rate of Cryopreserved Stem Cells

Post Your Comments:

( he spread of influenza viruses among hu...)HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove,Superior at International Conference,Health